石幽
07-07
维立志博的核心产品LBL-024,是全球首个冲进关键临床的4-1BB双抗,希望上市能让我感受到首个的含金量
免责声明:上述内容仅代表发帖人个人观点,不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP,发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":454067047973248,"tweetId":"454067047973248","gmtCreate":1751878306157,"gmtModify":1752717069828,"author":{"id":4130491074501500,"idStr":"4130491074501500","authorId":4130491074501500,"authorIdStr":"4130491074501500","name":"石幽","avatar":"https://static.tigerbbs.com/35abfb387b646fb639e8a59226ec46e6","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body>维立志博的核心产品LBL-024,是全球首个冲进关键临床的4-1BB双抗,希望上市能让我感受到首个的含金量</body></html>","htmlText":"<html><head></head><body>维立志博的核心产品LBL-024,是全球首个冲进关键临床的4-1BB双抗,希望上市能让我感受到首个的含金量</body></html>","text":"维立志博的核心产品LBL-024,是全球首个冲进关键临床的4-1BB双抗,希望上市能让我感受到首个的含金量","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/454067047973248","repostId":0,"isVote":1,"tweetType":1,"viewCount":475,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["91000","09887"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":92,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/454067047973248"}
精彩评论